HD-OPM Archive

Kidney health and the heart

How kidney function and heart disease feed each other, which tests actually show how well your kidneys are working, and what the group's posts say about medications, diet and supplements that help or harm the kidneys.

16 min read57 group posts cited43 studies discussed2 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Creatinine-based eGFR alone is not enough: cystatin C eGFR and creatinine eGFR disagree in about 30% of people, and the 2026 ESC guideline summary says to test both eGFR and urine albumin-to-creatinine ratio (uACR) in everyone with cardiovascular disease.
  • Albuminuria (albumin in the urine) is described in the ESC summary as a cardiovascular vital sign that predicts CKD progression, heart failure, atherosclerotic events and cardiovascular death.
  • SGLT2 inhibitors slow CKD progression regardless of diabetes status in meta-analyses; in SURPASS-CVOT, tirzepatide cut major kidney events by 23% versus dulaglutide; in the REMODEL study, semaglutide reduced albuminuria by 40%.
  • Atorvastatin is generally preferred over rosuvastatin in CKD (under 2% versus about 30% renal excretion); high-dose rosuvastatin (40 mg) lowered eGFR in the PLANET trials.
  • Higher protein intake was not linked to GFR decline in people with normal kidney function (28 RCTs, 1,358 adults), but low-protein diets still have a role in established CKD, and people with kidney problems should avoid potassium salt substitutes.
In this summary
  1. Why the kidneys and the heart are linked
  2. How to measure kidney health
  3. What damages the kidneys, and what protects them
  4. Diet, salt and supplements
  5. Nuances and caveats
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Kidney disease and heart disease are so tightly entangled that the group's admins and the latest guidelines they share treat them as two sides of one problem. Each condition accelerates the other: reduced kidney function raises cardiovascular risk, and protecting against atherosclerosis lowers the risk of later kidney disease.12 Gokhan Can notes that chronic kidney disease (CKD) almost always accompanies heart disease.3

The practical consequence is that kidney health deserves its own monitoring and its own protective strategy. The group's posts stress three ideas: measure kidney function properly (creatinine alone misses things), treat the shared roots (blood pressure, diabetes, excess visceral fat, lipids), and be careful with drugs, supplements and salt substitutes that kidneys have to clear.456

This article is a summary of those discussions, not medical advice. Where a recommendation is attributed to an admin, it is their view, and the group's admins repeatedly suggest discussing kidney-related decisions with your doctor.

3 in 4US adults may have cardiovascular-kidney-metabolic (CKM) syndrome, per the AHA7
30%of people get different answers from creatinine and cystatin C eGFR4
23%lower risk of major kidney events on tirzepatide than dulaglutide (SURPASS-CVOT post-hoc)8
40%less albuminuria on semaglutide in the REMODEL study9

Why the kidneys and the heart are linked

One syndrome, several organs

The 2026 European Society of Cardiology (ESC) guideline summary shared by Louis Nervegna says cardiovascular disease and CKD should be managed together as one "cardiorenal syndrome", because treating them in isolation misses prevention opportunities.1 The American Heart Association (AHA) uses the umbrella term cardiovascular-kidney-metabolic (CKM) syndrome and states that at least 3 in 4 US adults may have it, and that it may be reversible. Louis argues heart, kidney and metabolic disease are, in aggregate, the same disease.7

A 2025 proposal called CARDIAL-MS (cardio-renal-diabetes-liver-metabolic syndrome) goes further, describing metabolic liver disease, diabetes, cardiovascular disease and kidney disease as a single progressive syndrome rooted in dysfunctional fat tissue and ectopic fat (fat deposited in the liver, muscle, pancreas and heart and kidney tissue).6 The shared text calls for early intervention beyond single risk factors, before multi-organ damage sets in.

The CARDIAL-MS proposal: dysfunctional fat tissue and visceral fat release fatty acids that end up in the liver, pancreas, heart and around the kidney, and the syndrome is staged from weight gain and ectopic fat (stage 1) to advanced cardio-renal-liver-metabolic disease (stage 4).
The CARDIAL-MS proposal: dysfunctional fat tissue and visceral fat release fatty acids that end up in the liver, pancreas, heart and around the kidney, and the syndrome is staged from weight gain and ectopic fat (stage 1) to advanced cardio-renal-liver-metabolic disease (stage 4).6

Organs that talk to each other

A shared review describes the kidney as a hub that communicates with the heart, brain, gut, liver and lungs, and whose dysfunction contributes to cardiorenal syndromes, cognitive decline and anemia.13 Gokhan shares a 2026 report that diseased kidneys release tiny particles called extracellular vesicles that appear toxic to the heart, which may help explain why more than half of people with advanced kidney disease develop cardiovascular problems.14

The kidneys also keep the heart's electrical system stable. They regulate blood potassium, and when function declines potassium can accumulate; severe hyperkalemia (high potassium) can disrupt the heart's rhythm and cause life-threatening arrhythmias.15 A shared explainer on calcium notes that CKD impairs phosphate excretion, lowers ionized calcium and can trigger secondary hyperparathyroidism, with low calcium prolonging the QT interval and causing arrhythmias.16

Kidney function in risk calculators

Louis points out that the AHA's PREVENT risk calculator for ages 30 to 79 without known cardiovascular disease accounts for kidney and metabolic disease and estimates 10- and 30-year risk of both atherosclerotic disease and heart failure. He warns it will underestimate risk in people who have had a heart attack or stroke, or who have significant atherosclerosis or a high calcium score.17 He also notes that eGFR is now one of the inputs, because of how strongly it predicts heart attack and stroke.1318

A JACC International piece he shares found kidney function remains a strong prognostic factor in older heart attack patients, and that physiology-guided complete revascularization was effective regardless of kidney function.18 Left ventricular hypertrophy (thickening of the heart's main pumping chamber) can also be caused by CKD, among other things.19

When it starts

A shared Cell 2025 study summary suggests the heart and kidneys are among the first major organs to show measurable age-related change, from the mid-30s to early 40s.20 A study in the American Journal of Kidney Diseases (Lee et al.) found that young adults with better cardiovascular health had lower later risk of both CVD and kidney disease, and that improving health over time helped, while maintaining it from the start helped most.2

How to measure kidney health

Beyond creatinine

Gokhan stresses that creatinine and creatinine-based eGFR (estimated glomerular filtration rate, a calculation of how much blood the kidneys filter per minute) are imperfect. Cystatin C, a protein used to estimate GFR, is independent of muscle mass and may be more accurate, particularly in mild or early disease. Creatinine eGFR and cystatin C eGFR can disagree in about 30% of people, so a combined CKD-EPI creatinine-cystatin C equation may give the best estimate.421

He also links a 2025 report that a mismatch between the two common kidney function tests predicts higher risk of kidney failure, heart disease and death; he gives no numbers.22 He describes his own experience: his creatinine eGFR had averaged about 100, but the combined estimate was 86, which made him realize his kidneys were in slightly worse shape than he had thought.23 Because his doctors rarely order cystatin C and similar tests, he orders them himself.24

The five stages of chronic kidney disease, from kidney damage with normal function (stage 1) to kidney failure (stage 5), with the share of kidney function left at each stage. From Gokhan's post on which kidney markers to track.
The five stages of chronic kidney disease, from kidney damage with normal function (stage 1) to kidney failure (stage 5), with the share of kidney function left at each stage. From Gokhan's post on which kidney markers to track.21

Urine tests catch early damage

The urine albumin-to-creatinine ratio (uACR) detects albuminuria, which Gokhan describes as an early marker of kidney damage that can appear before eGFR falls.421 The 2026 ESC summary agrees: a patient may have substantial albuminuria and high cardiovascular risk despite a relatively preserved eGFR, so creatinine alone is not adequate screening. It recommends testing eGFR and uACR at diagnosis in everyone with cardiovascular disease, treating albuminuria as a "cardiovascular vital sign", and repeating both at least annually in people with cardiovascular disease, diabetes or CKD.1

Gokhan's ranking of five tests

Gokhan ranks five tests for monitoring kidney health, especially for people on many supplements or drugs:

  1. Cystatin C (very high usefulness).
  2. A chemistry panel, blood count and lipids, which includes creatinine and creatinine eGFR (very high).
  3. Albumin-to-creatinine ratio on a random urine sample (high).
  4. Urine protein-to-creatinine ratio (high).
  5. Routine urinalysis (moderate; more general and possibly redundant if the others are done).

He suggests tracking these at least annually, or more often at high risk, and says he personally trusts Life Extension for ordering them in the US.421

What damages the kidneys, and what protects them

Blood pressure, diabetes, Lp(a) and excess fat

A summary of the 2025 AHA/ACC blood pressure guideline shared by Louis says about 57% of men and 53% of women aged 45 to 59 have blood pressure above 130/80 mmHg (about 84% at ages 75 to 80), and that elevated pressure is a powerful risk factor for CKD as well as coronary disease, stroke and dementia.5

High blood pressure, a major driver of CKD, is the norm by middle ageShare of US adults with blood pressure above 130/80 mmHg, 2025 AHA/ACC guideline summary
Men aged 45–5957%
Women aged 45–5953%
Adults aged 75–80about 84%
The share is even higher with the stricter 120/80 cutoff. Source: 5
Show data
Value
Men aged 45–5957%
Women aged 45–5953%
Adults aged 75–80about 84%

Louis shares work from the Copenhagen General Population Study, relayed by Borge Nordestgaard, that genetically high Lp(a) appears to be a direct cause of CKD (Mendelian randomization and observational evidence), and advises people with high Lp(a) to monitor and protect their kidneys.2526

The CARDIAL-MS framework and the AHA's CKM concept both point to excess and misplaced body fat as a root cause, which connects kidney protection with weight loss and metabolic health.67

Gut-related ideas

  • A Cell Reports Medicine study shared by Louis found that constipation raised blood levels of toxins such as p-cresol sulfate and indoxyl sulfate, even in healthy people, and that these are particularly burdensome to the kidneys. Once or twice daily bowel movements, along with more fruit and vegetables, water, exercise and a plant-dominant diet, characterized the "Goldilocks" group. This was a cross-sectional study.27
  • Gokhan shares an explainer on imidazole propionate, a metabolite made by gut bacteria and elevated in conditions including kidney disease; it describes a diverse, high-fiber microbiome as protective.28
  • He also shares mouse and early human data. A gut-bacteria peptide called corisin tracked with severity of diabetic kidney disease and, in mice, a neutralizing antibody reduced kidney damage.3 A phase II trial of 118 CKD patients found the constipation drug lubiprostone (16 micrograms daily) preserved eGFR over 24 weeks versus decline on placebo, apparently through a microbiome shift that raised spermidine rather than by lowering uremic toxins.29 These are early findings.
  • Another observation is that TMAO, a compound the liver makes from gut-derived TMA, is filtered out by the kidneys, so better kidney function means lower TMAO; whether TMAO directly causes heart disease is described as unresolved.30

Medicines that protect the kidneys

SGLT2 inhibitors. Louis shares a JAMA editorial summarizing meta-analyses showing these drugs consistently reduce kidney disease progression and hospitalizations across all eGFR and albuminuria subgroups, regardless of diabetes status, including in advanced CKD or low albuminuria.10 A mechanism summary credits improved endothelial function and reduced inflammatory signaling in heart and kidney.31 A second editorial notes they also consistently raise hemoglobin and hematocrit, which may help anemia management.32

GLP-1 based drugs. In a post-hoc analysis of SURPASS-CVOT (people with type 2 diabetes and heart disease), tirzepatide gave 23% lower major kidney event risk than dulaglutide (30% lower in low-to-moderate CKD, 21% in high-risk CKD), with slower eGFR decline and reduced progression of macroalbuminuria.8 In the REMODEL mechanistic study, semaglutide in type 2 diabetes with CKD reduced albuminuria by 40% and kidney and perirenal fat. Louis's reading is that the benefit comes from negative energy balance, with the drugs simply making calorie restriction easier; that is his interpretation, not the trial's conclusion.9 A Nature Biotechnology editorial reports pharma speakers asking whether GLP-1 drugs might be the first longevity drugs, given benefits that include kidney disease, while a mouse study showed lifespan extension in elderly female mice.3334

Summary of the SURPASS-CVOT kidney analysis (13,165 people with type 2 diabetes and atherosclerotic disease, median 4 years): cumulative kidney events on tirzepatide versus dulaglutide overall and by CKD risk, with hazard ratios, event counts and the drivers of the benefit (less new macroalbuminuria, fewer large eGFR declines).
Summary of the SURPASS-CVOT kidney analysis (13,165 people with type 2 diabetes and atherosclerotic disease, median 4 years): cumulative kidney events on tirzepatide versus dulaglutide overall and by CKD risk, with hazard ratios, event counts and the drivers of the benefit (less new macroalbuminuria, fewer large eGFR declines).8

Statins. Louis shares that atorvastatin is generally preferred in CKD: it has under 2% renal excretion and needs no dose change in non-dialysis CKD stages 1 to 5, while rosuvastatin is about 30% renally excreted, needs dose reduction when eGFR is below 30 (often a maximum of 10 mg in severe CKD) and at high doses can cause reversible proteinuria or hematuria. The summary adds that KDIGO advises a statin with or without ezetimibe in non-dialysis CKD stages 3 to 5, and that renal benefits of statins are modest, with cardiovascular risk reduction being the main aim.3536 In the PLANET I and II trials, in patients with proteinuria, rosuvastatin 40 mg lowered eGFR and had more renal adverse events including acute kidney injury, while atorvastatin 80 mg reduced proteinuria and preserved kidney function. Louis adds that kidney function typically returns to baseline when the drug is stopped, and that standard rosuvastatin doses are safe for the vast majority.37 A teaching card he first shared said atorvastatin improved eGFR; he later corrected the typo, stating that atorvastatin improved proteinuria but had no effect on eGFR.38 A post-hoc analysis of 6 double-blind trials (30,621 patients) found atorvastatin improved kidney function over time in a dose-dependent way, and that improvement was associated with lower cardiovascular risk.39

AtorvastatinRosuvastatin
Renal excretionUnder 2%About 30%
Dose in CKD (not on dialysis)No change needed in stages 1 to 5Reduce when eGFR is below 30; often 10 mg maximum in severe CKD
Kidney effects at high doseReduced proteinuria (80 mg in PLANET)Reversible proteinuria or hematuria; 40 mg lowered eGFR in PLANET

The table summarizes the posts cited above.3537

Metformin. An editorial Louis shares notes that metformin was once avoided in CKD for fear of lactic acidosis; labels were widened in 2016 to eGFR 30 to 59, but guidelines still advise against it below eGFR 30 because of higher lactic acidosis hospitalization risk, and the editorial asks whether benefits might outweigh harms.40 In a later post Louis says patients with kidney dysfunction need to be careful, noting that metformin may protect healthy kidneys but that this may not hold once function is impaired, citing a retrospective cohort.41 The two posts therefore reflect an open question.

Bempedoic acid. A summary of a statin-intolerant trial (4,206 patients) reported fewer cardiovascular events but also raised serum creatinine, uric acid and liver enzymes as adverse effects.42

Drugs and substances that can harm

  • Louis says misuse of over-the-counter acetaminophen (paracetamol) and ibuprofen can cause serious liver and kidney damage, and calls this a larger concern than fears about turmeric or green tea.43
  • He agrees ibuprofen is "very rough on the kidneys", and that chronic NSAID use (not aspirin) can worsen heart failure and hypertension and raise heart attack and stroke risk, though occasional use is considered fine.1244
  • Severe hypercalcemia (too much calcium) can cause cardiac arrest, coma or kidney failure; a coroner's warning concerned an 89-year-old who died of vitamin D toxicity after at least nine months of supplements.45

Diet, salt and supplements

Protein

Louis shares evidence that protein does not harm healthy kidneys. A 10-year cohort with iohexol-measured GFR found higher self-reported protein intake was not associated with GFR decline in adults largely free of CKD.46 A review by Stuart Phillips against the Brenner hyperfiltration hypothesis cites a pooled analysis of 28 RCTs (1,358 adults without kidney disease) with no meaningful effect on GFR, and an 11-year follow-up of 1,624 women with no decline. Louis adds that high protein can cause harm in people with existing kidney problems, which is why low-protein diets remain part of standard nephrology care; a Cochrane review supports very low-protein diets in stage 4-5 CKD.47 Louis separately cautions that the "high-protein craze" is not evidence-based, noting an ICU trial of 3,397 patients where higher-protein feeding made no difference to survival or kidney outcomes.48

Salt, potassium and stones

Louis recommends a 50:50 salt and potassium chloride blend for lowering sodium while raising potassium, but warns that people with kidney problems should not use potassium salts because of the danger of high potassium and fatal cardiac arrest.1115

For kidney stones, he summarizes American Urological Association guidance: calcium oxalate stones are about 80% of stones; all stone formers should aim for urine volume of at least 2.5 liters daily; patients with high urinary calcium should limit sodium and consume 1,000-1,200 mg of dietary calcium daily; those with low urinary citrate should eat more fruit and vegetables and limit non-dairy animal protein; and potassium citrate may be offered for recurrent calcium stones with low urinary citrate.49 He also shares videos on why excess sodium raises stone risk.5051

Foods and supplements: mostly early or mixed evidence

  • In a randomized trial in prediabetes, daily avocado plus mango for 8 weeks improved vascular function and some kidney markers including eGFR, though cholesterol, blood sugar and inflammation did not change.52
  • A 2000 randomized placebo-controlled trial of coenzyme Q10 in chronic renal failure reported that 36.2% of patients on CoQ10 needed dialysis versus 90% on placebo. The post says it is not claiming CoQ10 reverses kidney disease and that the research exists; the trial is old, and confirmation in larger recent trials matters.53
  • Niacin reduced CKD and vitamin D3-induced vascular calcification in mice. Louis stresses it is preclinical, and that niacin failed to improve outcomes in two large trials with high-dose statins and should not be combined with high-dose statins.54
  • A review of vitamin K2 and coronary calcium notes that some CKD trials were null, and that K2 is not yet a standard therapy.55
An old CoQ10 trial reported far fewer patients needing dialysisShare of patients with chronic renal failure who needed dialysis, CoQ10 versus placebo (randomized, double-blind, published in 2000)
CoQ1036.2%
Placebo90%
A single old trial; it needs confirmation in larger, recent trials before it can guide treatment. Source: 53
Show data
Value
CoQ1036.2%
Placebo90%

Nuances and caveats

  • A normal creatinine does not mean healthy kidneys. The ESC summary and Gokhan both stress that albuminuria and cystatin C can reveal problems that creatinine eGFR misses.14
  • Many items are early evidence. Corisin, lubiprostone, niacin, extracellular vesicles and the semaglutide aging study are mouse or phase II data.3293454
  • Low values are not always good. Louis explains that observational U-shaped curves arise partly from reverse causality: for example, liver or kidney disease lowers A1C, so a low A1C is not automatically good.5657
  • Admin interpretations versus trial conclusions. Louis's view that GLP-1 kidney benefits mainly reflect calorie restriction is his interpretation.9
  • Observational findings. The cystatin mismatch report, young-adult cardiovascular health study and bowel movement study are associations.22227

What this means for you

These are ideas the admins and shared sources raise; discuss them with your doctor.

  • Ask for both eGFR (ideally including cystatin C) and a urine albumin-to-creatinine ratio, not just creatinine.14
  • Track kidney markers at least annually, more often if you take many drugs or supplements or are at high risk.4
  • Know your blood pressure and keep it controlled; it is a major driver of CKD.5
  • If you have high Lp(a), diabetes or metabolic syndrome, treat kidney monitoring as part of your plan.725
  • If you have CKD, ask whether an SGLT2 inhibitor is suitable, and discuss statin choice and dose (atorvastatin is generally preferred; rosuvastatin may need dose limits).1035
  • Avoid potassium-based salt substitutes if your kidneys are impaired, and discuss protein intake with a nephrologist if you have established CKD.1147
  • Be cautious with chronic NSAID use and with high-dose vitamin D or other supplements.1245

Frequently asked questions

Is eGFR from creatinine enough?

According to Gokhan, no. Creatinine and cystatin C eGFR are discordant in about 30% of people, and urine tests catch early damage that eGFR may miss.4

What is albuminuria and why does a heart patient care?

It is albumin leaking into the urine. The ESC summary calls it a cardiovascular vital sign because rising uACR predicts CKD progression, heart failure, atherosclerotic events and cardiovascular death.1

Does a high-protein diet damage the kidneys?

In people with normal kidney function, the pooled trials and cohort shared in the group found no meaningful harm. In established CKD, low-protein diets are standard nephrology care.4647

Which statin is better for the kidneys?

Louis shares that atorvastatin is generally preferred in CKD, with no renal dose adjustment, whereas rosuvastatin needs dose limits at low eGFR and high doses (40 mg) lowered eGFR in PLANET. For most people on standard doses, rosuvastatin is considered safe.3537

Can I use a potassium salt substitute?

Louis uses a 50:50 sodium and potassium blend himself but warns people with kidney problems not to, because high potassium can cause fatal cardiac arrest.11

The evidence behind this summary43 studies · 4 meta-analyses · 9 trials · 1 MR · 4 observational

The 57 group posts cited above discuss 43 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 4Randomized trials 9Mendelian randomization 1Observational studies 4Reviews & guidelines 12Animal & lab studies 4Other sources 9

Strongest evidence discussed

All 43 studies and sources
Sources from the group (57)
  1. 2026 ESC guidelines: manage CVD and CKD together as one cardiorenal syndrome Louis Nervegna · Aug 30, 2026 · Facebook
  2. Good cardiovascular health in young adulthood lowers later risk of CVD and kidney disease Louis Nervegna · Aug 26, 2025 · Facebook
  3. Gut-bacteria peptide corisin drives diabetic kidney fibrosis in mice Gokhan Can · Aug 26, 2025 · Facebook
  4. Measuring kidney health: add cystatin C and urine albumin-to-creatinine to creatinine eGFR Gokhan Can · Sep 09, 2024 · Facebook
  5. 2025 US blood pressure guideline: 57% of men and 53% of women aged 45-59 are above 130/80 Louis Nervegna · Oct 14, 2025 · Facebook
  6. CARDIAL-MS proposed as one multisystem metabolic disease (heart, kidney, liver, diabetes) Louis Nervegna · Aug 04, 2025 · Facebook
  7. AHA: at least 3 in 4 US adults may have reversible CKM syndrome Louis Nervegna · Jul 13, 2026 · Facebook
  8. Tirzepatide cut major kidney events 23% vs dulaglutide in SURPASS-CVOT post-hoc analysis Louis Nervegna · May 13, 2026 · Facebook
  9. Semaglutide REMODEL trial: 40% less albuminuria, and a calorie-restriction interpretation Louis Nervegna · Oct 01, 2026 · Facebook
  10. SGLT2 inhibitors slow CKD progression regardless of diabetes status, per meta-analyses Louis Nervegna · Jan 20, 2026 · Facebook
  11. A 50:50 salt/potassium blend cuts sodium and adds potassium; avoid with kidney disease Louis Nervegna · Dec 04, 2025 · Facebook
  12. Chronic ibuprofen and NSAID use raises heart attack, stroke, kidney and BP risks Louis Nervegna · Jan 24, 2026 · Facebook
  13. Kidney function (eGFR) now an input in the AHA risk calculator for heart attack and stroke Louis Nervegna · Aug 25, 2025 · Facebook
  14. Diseased kidneys release extracellular vesicles that may be toxic to the heart Gokhan Can · Feb 01, 2026 · Facebook
  15. Hyperkalemia can stop the heart, so kidney disease patients must watch potassium Louis Nervegna · Nov 06, 2026 · Facebook
  16. How calcium balance goes wrong: PTH, vitamin D and kidney roles in low and high calcium Louis Nervegna · Oct 17, 2025 · Facebook
  17. AHA PREVENT calculator replaces Pooled Cohort Equations for ages 30-79 Louis Nervegna · Jan 25, 2024 · Facebook
  18. Kidney function is a major CVD driver and now an input in the new AHA risk calculator Louis Nervegna · Dec 16, 2025 · Facebook
  19. HCM, athlete's heart and LVH look alike on imaging but differ greatly in risk Louis Nervegna · Apr 03, 2024 · Facebook
  20. Cell 2025 study maps when different organs begin to show signs of aging Louis Nervegna · Jan 14, 2026 · Facebook
  21. Kidney health tracking: cystatin C, urine albumin/creatinine and more beyond creatinine Gokhan Can · Sep 28, 2024 · Facebook
  22. Cystatin C blood test may flag kidney and heart risk that creatinine misses Gokhan Can · Nov 07, 2025 · Facebook
  23. Personal labs on tirzepatide/retatrutide and 5 mg rosuvastatin: LDL 61, ApoB 58, eGFR 86 Gokhan Can · Oct 08, 2024 · Facebook
  24. Ordering hsCRP, ApoB, insulin and cystatin C yourself when doctors do not Gokhan Can · Jul 05, 2025 · Facebook
  25. Genetically high Lp(a) appears to be a direct cause of chronic kidney disease Louis Nervegna · Oct 17, 2024 · Facebook
  26. High Lp(a) is linked to chronic kidney disease, reports Medscape Louis Nervegna · Jul 06, 2024 · Facebook
  27. Bowel movement frequency of once or twice daily linked to better gut and overall health Louis Nervegna · Mar 19, 2025 · Facebook
  28. Imidazole propionate: how gut bacteria make it from histidine and how to lower it Gokhan Can · Jul 18, 2025 · Facebook
  29. Lubiprostone preserved kidney function in a 118-patient phase II CKD trial Gokhan Can · Aug 30, 2025 · Facebook
  30. Whether TMAO directly causes heart disease is unresolved; gut bacteria and insulin matter Louis Nervegna · Jun 10, 2024 · Facebook
  31. SGLT2 inhibitors protect heart and kidneys via vascular and anti-inflammatory effects Louis Nervegna · Jan 23, 2026 · Facebook
  32. SGLT2 inhibitors consistently raise hemoglobin and hematocrit, a possible anemia benefit Louis Nervegna · Oct 24, 2026 · Facebook
  33. Nature Biotechnology editorial asks whether GLP-1 drugs are the first longevity drugs Louis Nervegna · Nov 24, 2025 · Facebook
  34. Semaglutide extended lifespan 12% in elderly female mice, hinting GLP-1 slows aging Louis Nervegna · Oct 29, 2026 · Facebook
  35. Atorvastatin is generally preferred over rosuvastatin in chronic kidney disease Louis Nervegna · Dec 08, 2025 · Facebook
  36. Which statin to choose: atorvastatin, rosuvastatin and other options by patient type Louis Nervegna · Oct 23, 2026 · Facebook
  37. Rosuvastatin can stress kidneys at high dose; atorvastatin appears kidney-friendly Louis Nervegna · Jul 13, 2026 · Facebook
  38. PLANET trial: atorvastatin preferred over rosuvastatin in CKD (with July 2026 correction) Louis Nervegna · Dec 06, 2025 · Facebook
  39. Atorvastatin improved kidney function dose-dependently across 6 RCTs with 30,621 patients Louis Nervegna · Oct 13, 2024 · Facebook
  40. AJKD editorial reconsiders metformin safety in advanced chronic kidney disease Louis Nervegna · Feb 16, 2025 · Facebook
  41. Metformin needs caution in impaired kidney function, though it may protect healthy kidneys Louis Nervegna · Feb 03, 2026 · Facebook
  42. Bempedoic acid cut CV events and may also dampen age-related inflammation Louis Nervegna · Jul 21, 2026 · Facebook
  43. Misuse of OTC painkillers harms liver and kidneys more than turmeric or green tea Louis Nervegna · Jul 10, 2025 · Facebook
  44. Methotrexate may lower heart disease risk in rheumatoid arthritis and be safer than NSAIDs Louis Nervegna · Oct 19, 2025 · Facebook
  45. Vitamin D overdose caused fatal hypercalcemia in an 89-year-old, UK coroner warns Louis Nervegna · Jan 21, 2026 · Facebook
  46. High protein intake not linked to kidney function decline in a 10-year measured-GFR cohort Louis Nervegna · Aug 15, 2026 · Facebook
  47. High protein does not harm kidneys in healthy people, but matters with kidney disease Louis Nervegna · May 24, 2026 · Facebook
  48. Large ICU RCT found no benefit from high-protein feeding; Louis cautions on protein hype Louis Nervegna · Jun 13, 2025 · Facebook
  49. Preventing calcium oxalate kidney stones: AUA guideline recommendations Louis Nervegna · Aug 01, 2025 · Facebook
  50. Video on why excess dietary sodium raises kidney stone risk Louis Nervegna · Jul 13, 2025 · Facebook
  51. Video: why excess dietary sodium raises kidney stone risk Louis Nervegna · Apr 30, 2026 · Facebook
  52. Daily avocado plus mango for 8 weeks improved vascular function in prediabetes Louis Nervegna · Apr 09, 2026 · Facebook
  53. CoQ10 trial in chronic kidney failure: 36% vs 90% needed dialysis Louis Nervegna · Oct 16, 2026 · Facebook
  54. Niacin inhibited vascular calcification in mice via SIRT1/SIRT6 activation Louis Nervegna · Dec 09, 2025 · Facebook
  55. Vitamin K2 slows coronary calcium mainly in severe calcification; event benefit unproven Gokhan Can · Dec 02, 2025 · Facebook
  56. U-shaped mortality curves for cholesterol, BMI, A1C and BP reflect reverse causality Louis Nervegna · Jun 12, 2024 · Facebook
  57. U-shaped mortality curves for cholesterol, BMI, A1C and BP reflect reverse causality Louis Nervegna · May 11, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary